Europe Protein A Resins Market

Europe Protein A Resins Market Size (2022 to 2027)

The Protein A Resins Market in Europe was worth USD 102.87 million in 2022 and is estimated to be growing at a CAGR of 7.8%, to reach USD 149.76 million by 2027.

The European protein A Resins market is expected to be driven by market Factors such as rising demand for biosimilars, increased investments in biosimilar product research and development. Also, increased awareness about alternative approaches to purify monoclonal antibodies, growing healthcare expenditure, and improving healthcare infrastructure.

On the other hand, significant market companies in the country have significantly impacted the market expansion.  Furthermore, increasing demand for immunotherapy medications for chronic disorders in developed countries such as Germany, UK, and France is expected to expand the regional market growth.

Alternative purification technologies such as ultrafiltration, crystallization, high-pressure folding, and capillary electrophoresis are, nevertheless, limiting issues for the. In addition, high prices have a negative impact on the industry's growth by influencing both affordability and protein A resin adoption rates. Protein A resin's high cost is another significant impediment to the market's growth. However, researchers' increased interest in synthetic biology is feeling the market for Protein A Resins in the European region. The efforts of researchers to develop a one-of-a-kind machine for synthesizing proteins give the market a competitive advantage.

This research report on the European Protein A Resins market has been segmented and sub-segmented into the following categories:

By Product Type: 

• Natural Protein A Resin
• Recombinant Protein A Resin

By Application: 

• Immunoprecipitation
• Antibody Purification

By Matrix Type: 

• Glass or Silica
• Agarose
• Organic Polymer  

By End Users: 

• Biopharmaceutical Manufacturers
• Clinical Research Laboratories
• Academic Institutions

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the European market had the second-largest share of the global protein A resins market in 2020, and it is likely to witness the same growth during the forecast period. Factors such as rising demand for biosimilars and increased investments in biosimilar product research and development are expected to fuel growth. Still, increased awareness about alternative ways to purify monoclonal antibodies is expected to stifle the protein A resins market. Another important stumbling block to protein growth is The high cost of these products in the resins market. Nevertheless, Europe is expected to witness the market due to the considerable presence of important pharmaceutical and biotechnological enterprises in the region and increased financing by a government organization for significant research initiatives connected to protein A resins in the region. In the countries such as Germany, the United Kingdom, France, and Spain, the resins market plays a vital role in the region and expands the European regional market growth.

Germany accounted for the largest share of the European protein A resins market in 2020, and it is anticipated to register a predominant share during the forecast period. The market growth is attributed to the rising prevalence of chronic illnesses, availability of advanced healthcare infrastructure, and favorable reimbursement policies.

On the other hand, the UK is more likely to record a significant share in the European protein A resins market during the forecast period. The Increasing research and development activities, supportive government policies, and growing demand for protein A resins in the country significantly fuel market growth.

KEY MARKET PLAYERS:

A few prominent companies operating in the Europe Protein A Resins Market profiled in this report are GE Healthcare, Repligen Corporation, Novasep, Tosoh Bioscience, GenScript, Thermo Fisher Scientific, and EMD Millipore and Expedeon Ltd.